Details for Patent: 11,571,425
✉ Email this page to a colleague
Which drugs does patent 11,571,425 protect, and when does it expire?
Patent 11,571,425 protects OPZELURA and is included in one NDA.
This patent has sixty-nine patent family members in thirty-four countries.
Drugs Protected by US Patent 11,571,425
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 11,571,425 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,571,425
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 084691 | ⤷ Subscribe | |||
Argentina | 124134 | ⤷ Subscribe | |||
Australia | 2011255443 | ⤷ Subscribe | |||
Australia | 2014202896 | ⤷ Subscribe | |||
Australia | 2016204689 | ⤷ Subscribe | |||
Australia | 2018201889 | ⤷ Subscribe | |||
Australia | 2020201151 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |